Consonance Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Consonance Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-137,000	Closed	-$1.52M	–	8
2022 Q1	$1.52M	Sell	137,000 -13,000	-9%	-$129K	2.58%	7
2021 Q4	$1.48M	Hold	150,000	–	–	0.97%	12
2021 Q3	$1.49M	Hold	150,000	–	–	0.82%	14
2021 Q2	$1.55M	Hold	150,000	–	–	0.19%	30
2021 Q1	$1.53M	Hold	150,000	–	–	0.16%	35
2020 Q4	$1.69M	Buy	+150,000	New	+$1.59M	0.16%	34

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Consonance Capital Management's MLTX Position: Q2 2022 in Review

Consonance Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 137,000 shares — an estimated $1.52M sold.

Consonance Capital Management first reported a position in MLTX in Q4 2020 and held it in 6 quarters. The position peaked at $1.69M in Q4 2020. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

Consonance Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
Consonance Capital Management sold 137,000 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $1.52M.
Consonance Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 6 quarters.
Consonance Capital Management's MoonLake Immunotherapeutics position peaked at $1.69M in Q4 2020.
23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Consonance Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.